1 SARS-CoV-2 screening in patients in need of urgent inpatient treatment in the Emergency
2 Department (ED) by digitally integrated point-of-care PCR: A clinical cohort study
3 Martin Möckel¹, Myrto Bolanaki¹, Jörg Hofmann², Angela Stein², Jennifer Hitzek¹, Fabian
4 Holert¹, Antje Fischer-Rosinsky¹ and Anna Slagman¹

5

6 ¹Department of Emergency and Acute Medicine, Charité – Universitätsmedizin Berlin,
7 Campus Mitte and Virchow and

8 ²Institute of Virology, Charité - Universitätsmedizin Berlin and Labor Berlin - Charité Vivantes
9 GmbH

10

11

12

13

14 Running title: SARS-CoV-2 screening in the ED

15

16 Word count: 2413

17

18

19

20

21

22

23

24

25

26

27 Correspondence to:

28 Univ.-Prof. Dr. med. Martin Möckel, FESC, FAHA

29 Department of Emergency and Acute Medicine

30 Campus Mitte and Virchow

31 Charité – Universitätsmedizin Berlin

32 Charitéplatz 1

33 10117 Berlin

34 Email: martin.moeckel@charite.de

35

36 **Abstract**

37 Patients in need of urgent inpatient treatment were recruited prospectively. A rapid point of
38 care PCR test (POC-PCR; Liat®) for SARS-CoV2 was conducted in the ED and a second PCR-
39 test from the same swab was ordered in the central laboratory (CL-PCR). POC-PCR analyzers
40 were digitally integrated in the laboratory information system.

41 Overall, 160 ED patients were included. A valid POC-PCR-test result was available in 96.3%
42 (n=154) of patients. N=16 patients tested positive for SARS-CoV-2 (10.0%). The POC PCR test
43 results were available within 102 minutes (median, IQR: 56-211), which was significantly
44 earlier compared to the CL PCR (811 minutes; IQR: 533-1289, $p < 0.001$). The diagnostic
45 accuracy of the POC- PCR test was 100%. The implementation and digital LIS integration was
46 successfully done. Staff satisfaction with the POC process was high.

47 The POC-PCR testing in the emergency department is feasible and shows a very high
48 diagnostic performance.

49 Trial registration: DRKS00019207

50 Introduction

51 The COVID-19 pandemic put major challenges on Emergency Departments (ED)
52 worldwide(1). One major aspect was that all urgent patients had to be treated mostly
53 without knowing the SARS-CoV-2 status as laboratory based polymerase chain reaction
54 (PCR)-test usually took at least 6-8 hours of turn-around-time (TAT)(2). The introduction of
55 rapid antigen testing had the advantage of faster results on the cost of false negative results.
56 Although some authors thought that false negative rapid antigen tests may due to low virus
57 concentrations only(3), we could show that this is not true in clinical practice and that
58 among false negatives are infectious patients with high virus load(4). Thus, specifically for

59 emergencies, which require immediate intervention or operation and probably airway-
60 management like patients with multiple trauma, acute myocardial infarction or stroke, a
61 rapid, point-of-care (POC) SARS-CoV-2 PCR test would be of utmost importance(5).
62 POC testing is standard in the ED for clinical chemistry parameters like lactate, electrolytes
63 or cardiac troponin. For molecular diagnostics there have been first attempts with influenza
64 POC testing(6). Due to the high importance of the test results, which touch regulatory
65 aspects like hygiene rules and due the fast disposition and transfers (i.e. operating theatre,
66 ICU) of the high urgent patients, a digital integration of the POC device in the LIS seems
67 mandatory. In addition, strict testing rules to guarantee correct results, staff safety and
68 reliable results information for all involved health care professionals have to be applied.
69 Finally, the used instrument and assay need to provide reliable results under routine
70 conditions(7).

71 Therefore, in the current study, a SARS-CoV-2 PCR POC analyzer was digitally integrated in
72 the LIS and tests were run by ED staff in high urgent patients.

73 Methods

74 *Patient population*

75 All inpatients are screened for SARS-CoV-2 in our ED. Patients were prospectively recruited
76 once it became clear that an acute intervention of any kind was indicated.

77 *Data collection and endpoints*

78 Clinical characteristics and in-hospital follow-up information of all included patients were
79 extracted from electronic medical records.

The primary endpoint of the analyses was turn-around-time (TAT) of the POC-PCR as compared to TAT of the CL-PCR in relation to the first intervention. Secondary endpoints were diagnostic performance, staff satisfaction with test handling and transfer of test results, patient safety and description of further clinical endpoints (e.g. stay on the intensive care unit (ICU), extra-corporal membrane oxygenation (ECMO), in-hospital mortality).

Statistical Analysis

Descriptive analyses included the calculation of relative and absolute frequencies as well as median and interquartile range (IQR). Statistical differences were calculated using the Chi-square test for categorical variables and the Mann-Whitney test for continuous variables. A p-value of less than 0.05 was considered statistically significant. Due to the exploratory nature of the analysis, no corrections were made for multiple testing.

Digital integration of POC analyzers

Liat® POC analyzers (Roche Molecular Systems) were connected to the laboratory information system via the hospital LAN system and Roche infinity POC middleware. The POC test was ordered via the laboratory channel, a barcode was generated and put on the test tube. A triple test cartridge (SARS-CoV-2, influenza A & B) was used. The barcode was scanned by the POC instrument and identified the order. Once the analyzer completed the test run, results were automatically transferred. In the central (molecular biology) laboratory the POC test results were automatically confirmed and transferred to the hospital information system. The LIS-HIS interface was refreshed every 15min. Thus with a 20min testing time on the Liat® analyzers, the SARS-CoV-2 POC test results were digitally available hospital wide within a maximum of 35min after the start of test.

Hygiene concept and test execution

As the work with potential contagious samples require specific hygiene rules, these were set up according to national regulations. One challenge was that these rules allow the SARS-CoV-2 sample handling outside a laboratory setting only, if it is performed by the protected person who did the swab. Therefore, we set up the procedure in the way that the POC test cartridge was filled in the isolation room of the patient. Once the cartridge was closed, it could be handled by another member of the staff, who started the test run of the instrument at a central location of the ED. The details of the test procedure are available in the supplemental material (S1). For standardization purposes known virus preparations and dilutions were measured. The transport media was directly pipetted into the test cartridge without further dilution in a buffer.

The digitally integrated use of the POC instrument in the ED is summarized in the figure 1.

Ethics

The Ethics committee of the Charité approved the study as an amendment to a previous POC influenza investigation (EA2/204/19). The study was registered in the German Clinical Trials Registry (DRKS00019207).

Results

Patient characteristics

The population of patients in urgent need of inpatient treatment (n=160) consisted of 10.0% of patients tested positive for SARS-CoV-2 in POC-PCR-testing (n=16) and 86.3% who were tested negative (86.3%). In 6 patients an invalid result occurred. Figure 2 shows the patient flow diagram.

Of all patient, 43.1% (n=69) were women and the median age was 68 years (IQR: 51-78).

In confirmed SARS-CoV-2 cases by POC-PCR-testing, the proportion of female patients was 50.0% (n=8) as compared to 41.3% (n=57) in patients who were tested negative for SARS-CoV-2 (table 1a). The most common symptoms in SARS-CoV-2 positive cases were Dyspnea (37.5%; n=6), fever and cough (25.0%; n=7 each) table 1b. Laboratory parameters are depicted in table 1b. Diagnostic accuracy of POC-PCR was compared to CL-PCR (reference method) in all patients in urgent need of inpatient treatment. The resulting diagnostic performance values are: sensitivity 100% (95%-CI: 79-100), specificity 100% (95%-CI: 97-100), PPV and NPV 100% (table 2). The most common reasons for urgent need of inpatient treatment were admission to ICU (25.0%; n=40), urgent operation (22.5%, n=36) and stroke (18.1%; n=29; table 3).

Primary endpoint

The POC PCR test was available within 102 minutes (median, IQR: 56-211) after admission, which was significantly earlier compared to the CL PCR (811 min; IQR: 533-1289, $p < 0.001$). In 77.4% of patients the first relevant intervention depending on the inclusion criteria (acute severe trauma, stroke, myocardial infarction, operation, intervention needed within 6 hours after presentation, ICU admission needed within 6 hours after presentation) was done within 6 hours (n=113). The POC test result was available before the intervention in 92.1% (n=129) compared to 5.4% test results from the CL (n=8). There were no positive influenza tests.

Standard sample measurements

We measured standard samples provided by the institute of virology with the following results.

Ct-values of the calibration samples (series on the same Liat® instrument)

148 G21124.1 (GE/mL 1.93E+07) = 18.6 [Ct ref. Cobas 6800: 25.2]

149 G21125.1 (GE/mL 2.76E+06) = 21.1 [Ct ref. Cobas 6800: 28.2]

150 G21126.1 (GE/mL 2.43E+05) = 24.5 [Ct ref. Cobas 6800: 32.0]

151 Ct-values of the dilutions

152 G21126-2 (1:10) = Ct 28.0

153 G21126-2 (1:100) = Ct 31.5

154 G21126-2 (1:1,000) Ct 35.5

155 G21126-2 (1:10,000) Ct 42 = negative

156 *Diagnostic performance*

157 Ct-values were converted into estimated virus concentrations per mL buffer using the
158 standards listed above. Levels below 10^6 per mL buffer are considered as “weak positive”,
159 between 10^6 and 10^7 are considered as “intermediate” and over 10^7 as high. Calculated virus
160 concentrations below 10^4 are labelled as “borderline” (repeat measurement after 24-48h).

161 *Clinical endpoints*

162 Clinical endpoint are listed in table 3.

163 *Staff satisfaction questionnaire*

164 The questionnaire comprised of 11 questions and the opportunity of free text. The
165 questionnaire is available in the supplement 2 (S2). N=37 members of staff, who were
166 involved in the operation of the POC instrument participated. 89% of respondents
167 performed more than 10 measurements with the Liat in and outside of the current study.
168 73% performed more than 25 measurements and stated that they can integrate the POC
169 testing very well into the treatment routine in the ED. More than 70% of respondents stated
170 they were satisfied with the usability of the devices and 62% were satisfied with sample
171 handling. In contrast 5% were unsatisfied with sample handling: holding the cartridges and

pipettes simultaneously as well as the need to pipette beside the patient were points of criticism.

In this current context 46% of the respondents were unsatisfied with hygienic conditions of sample processing. Main aspects for concerns were the location of the devices and the safety for employees and patients. 57% of respondents stated they were satisfied with display of results, 38% were undecided. Medical employees indicated that there should be greater ability to print the results directly at the POC instrument. Furthermore the results of POC testing had various effects. For one, they had an impact on interactions with the patients for 81% of the respondents, in addition, 86% of the respondents stated that the available results were valued by further departments/wards.

Discussion

The current study confirms(8, 9) the high accuracy of the Liat® SARS-CoV-2 POC PCR test and for the first time the feasibility of use in a large and busy ED with digital integration in the laboratory and hospital information systems (see figure 1).

POC test performance

The use of POC systems are always intended to shorten the turn-around-time (TAT). As in other studies, this could be shown here. Nevertheless, more important than the pure TAT is (1) the “time to actionable result” time of the attending physicians and (2) whether any important clinical action follows a POC test result. In our study we could clearly show that a majority of SARS-CoV-2 POC test results was available before an urgent care process has been started. Nevertheless, although the pure testing time of the instrument is 20min, the median time from admission to result was 102min, reflecting that there has been a delay in

the implementation of the ED test strategy at the time of this study. As the test strategy is now standard in our institution and test capacities are sufficient, this time may be shorter in current routine care. The accuracy of the test results was 100%, although semi-quantification revealed some differences (see table 2). The sensitivity of the POC instrument seems to be comparable to the reference standard, which is an advantage compared to other POC PCR systems, where 1-2% false negatives are reported(7).

Digital integration

Digital integration is a success factor under several aspects: (1) The digital order of the test including a standard label for the test tube ensures that the risk to mix up samples is minimized. (2) As the major incentive for the SARS-CoV-2 POC PCR is to speed up a complex pathway for emergency patients, it is mandatory that the test results are available for treating units including the operating theatre, intensive care and stroke units etc. In addition, tests need to be repeated and for this, it is most beneficial to have the results of the initial POC testing in the same system as the other laboratory test results. (3) The laboratory with experts for molecular test are automatically in the loop and contribute to quality management. Meanwhile we transfer also the cycle threshold values and a standard laboratory report is done on the basis of the POC test. (4) The POC PCR is a more expensive measure and reimbursement needs to be complete. Having all results in the central system ensures that no test is overseen. We believe that the complete digital integration should be the standard of POC in the ED in general and have established this way of collaboration with the central laboratory earlier for POC of Troponin T(10).

Staff satisfaction

The use of high end POC devices in the ED requires trained staff, who are able to follow demanding test protocols as in this study due to hygiene rules as described in detail above (see also S1 for details). Thus, it is most important to assess the staff perspective on innovative POC test strategies. The staff was mostly satisfied with the technical aspects including sample handling and the ease of use of the instrument. A major concern, expressed by 46% of the participants were hygiene aspects of the test procedure. Although the test process follows strictly the regulations, many nurses feel uneasy with the step of pipetting a potential infectious sample although being sufficiently protected. We think that one solution of for this challenge could be the use of inactivating lysis buffer in the test tubes(11). Currently, only transport media and saline are approved for the use with the instrument.

Finally, the majority of participants valued that all admission processes and the interaction with patients and colleagues is supported by the POC PCR.

Perspectives

The following future developments are necessary for the continuation of molecular POC testing in the ED.

1. Use of tubes with inactivating lysis buffer, to make the test safer for the users.
Alternatively, laboratory workbenches needs to be integrated in the ED, which may be suitable some but no everywhere.
2. Transfer of cycle threshold (Ct) values to the LIS. Meanwhile, the Ct values are used to estimate virus concentrations in the buffer of swabs on the basis of measurement of virus standards. On the peak of the SARS-CoV-2 waves with many positive samples, this has less importance than in lower incidence times, because now, frequently

weak positive signals occur and those patients must not be sent to a COVID-19 ward, where they are placed at risk for an infection, which they might not have at admission. This innovation has been actually released and is tested currently in our ED. Ct-values are automatically translated into a medical report of positive test results as being “to be controlled”, “weak positive” [$< 10^6$ virus copies/mL buffer] or “strong positive” [$> 10^7$ virus copies/mL buffer] or intermediate positive in between of the other two categories.

3. Future epidemiology of SARS-CoV-2 and other virus diseases will require a more differentiated test approach. Thus, in an actual very low incidence phase and no influenza at all, we would prefer to use a single SARS-CoV-2 test. In pediatrics the combination of SARS-CoV-2 and RSV would be interesting and at winter time the current triple test or even the addition of RSV would be beneficial. Finally, for future instrument development, a standardization of the PCR cycles with central laboratory instruments could help.

Clinical significance

Our study show that a fully digital integrated POC PCR test strategy improves fast and safe emergency processes in urgent patients under pandemic conditions in the ED.

Conclusions

The POC-PCR testing in the emergency department is feasible and shows a very high diagnostic performance. The digital process integration is key for a high clinical impact in patients with acute indication for inpatient treatment.

Acknowledgement

We acknowledge Clinical Research Unit (CRU) by Berlin Institute of Health (BIH), 10178 Berlin, Germany for providing support regarding the use of the data management software (RedCap). We thank Dr. Victor Corman, Institute for Virology, Charité – Universitätsmedizin Berlin, providing the standard virus samples.

Conflicts of interest

The authors declare funding from Roche Molecular Systems for the submitted work.

Funding

This study was supported by a research grant from Roche Molecular Systems.

References

1. Möckel M, Bachmann U, Behringer W, Pfäfflin F, Stegemann MS. How emergency departments prepare for virus disease outbreaks like COVID-19. European journal of emergency medicine : official journal of the European Society for Emergency Medicine. 2020;27(3):161-2.
2. Möckel M, Stegemann MS, Burst V, Kümper P, Risse J, Koehler FC, et al. Which parameters support disposition decision in suspected COVID-19 cases in the emergency department (ED): a German clinical cohort study. BMJ open. 2021;11(3):e044853.
3. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity — A Strategy for Containment. New England Journal of Medicine. 2020;383(22):e120.
4. Möckel M, Corman VM, Stegemann MS, Hofmann J, Stein A, Jones TC, et al. SARS-CoV-2 antigen rapid immunoassay for diagnosis of COVID-19 in the emergency department. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals. 2021;26(3):213-20.
5. Esbin MN, Whitney ON, Chong S, Maurer A, Darzacq X, Tjian R. Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection. Rna. 2020;26(7):771-83.

6. Perlitz B, Slagman A, Hitzek J, Riedlinger D, Möckel M. Point-of-care testing for influenza in a university emergency department: A prospective study. *Influenza and other respiratory viruses*. 2021.
7. McDonald S, Courtney DM, Clark AE, Muthukumar A, Lee F, Balani J, et al. Diagnostic Performance of a Rapid Point-of-care Test for SARS-CoV-2 in an Urban Emergency Department Setting. *Acad Emerg Med*. 2020;27(8):764-6.
8. Hansen G, Marino J, Wang ZX, Beavis KG, Rodrigo J, Labog K, et al. Clinical Performance of the Point-of-Care cobas Liat for Detection of SARS-CoV-2 in 20 Minutes: a Multicenter Study. *Journal of clinical microbiology*. 2021;59(2).
9. Tsang HF, Leung WMS, Chan LWC, Cho WCS, Wong SCC. Performance comparison of the Cobas® Liat® and Cepheid® GeneXpert® systems on SARS-CoV-2 detection in nasopharyngeal swab and posterior oropharyngeal saliva. *Expert review of molecular diagnostics*. 2021;21(5):515-8.
10. Slagman A, von Recum J, Möckel M, Holert F, Meyer Zum Büschenfelde D, Müller C, et al. Diagnostic performance of a high-sensitive troponin T assay and a troponin T point of care assay in the clinical routine of an Emergency Department: A clinical cohort study. *International journal of cardiology*. 2017;230:454-60.
11. Daum LT, Fischer GW. Rapid and Safe Detection of SARS-CoV-2 and Influenza Virus RNA using Onsite qPCR Diagnostic Testing from Clinical Specimens Collected in Molecular Transport Medium. *The journal of applied laboratory medicine*. 2021.

Contributorship Statement

All authors were involved in the conception and design of the study. MB, AFR and AS planned the acquisition of data. MB and AS conducted the statistical analysis. JH and AS set up the connection to the virology laboratory, performed and interpreted the confirmation tests and supervised the study from the laboratory side. FH set up the local process standard and supervised test activities. JHi was responsible for the questionnaire. MM, MB and AS drafted the manuscript and serve as guarantors for the manuscript. All authors were involved in the interpretation of data, critically revised the manuscript for important intellectual content, approved the final version to be published and agreed to be

accountable for all aspects of the work. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Table legends

Table 1

a. Demographic and clinical characteristics of all patients who were tested positive or negative for SARS-CoV-2 by POC-PCR; values are median (25%-75% percentiles); *, in n=6 patient an invalid result occurred on the POC instrument. BMI, body mass index; BP, systemic arterial blood pressure.

b. Symptoms and risk factors of all participants and patients who were tested positive or negative for SARS-CoV-2 by POC-PCR; *, in n=6 patient an invalid result occurred on the POC instrument.

Table 2. Diagnostic accuracy of POC-PCR as compared to CL-PCR (reference method) in patients in urgent need for treatment. The resulting diagnostic performance values are: sensitivity 100% (95%-CI: 79-100), specificity 100% (95%-CI: 97-100), PPV and NPV 100%.

Table 3. Clinical endpoints of all patients who were tested positive or negative for SARS-CoV-2 by POC-PCR; *, in n=6 patient an invalid result occurred on the POC instrument.

Figure Legends

Figure 1. Process of the digitally integrated SARS-CoV-2 POC

Figure 2. Patient flow diagram. For this implementation and feasibility study, n=200 tests were available.

Table 1a	All patients*	SARS-CoV-2	SARS-CoV-2 POC
	(n=160)	POC-PCR positive patients (n=16)	PCR negative patients (n=138)
Women % (n)	43.1 (69)	50.0 (8)	41.3 (57)
Age [years]	68 (51-78)	68 (57-78)	67 (51-78)
BMI [kg/m²]	25 (22-31)	30 (25-33)	24 (22-29)
Vital signs			
BP systolic [mmHg]	135 (115-155)	128 (108-150)	135 (116-155)
BP diastolic [mmHg]	81 (69-90)	75 (60-90)	82 (71-93)
Heart rate [1/min]	90 (77-106)	88 (71-106)	92 (79-107)
Body temperature [°C]	36.7 (36.1-37.4)	36.9 (36.2-38)	36.6 (36-37.3)
Respiratory rate [1/min]	17 (15-22)	23 (16-20)	17 (15-22)
Oxygen saturation [%]	98 (94-100)	94 (86-98)	98 (95-100)
Laboratory values			
pH (nmiss=15)	7.36 (7.33-7.41)	7.38 (7.31-7.44)	7.37 (7.33-7.40)
Sodium [mmol/L] (nmiss=4)	140 (136-142)	140 (137-142)	140 (136-142)
Potassium [mmol/L] (nmiss=19)	4.1 (3.8-4.5)	4.4 (3.9-4.9)	4.1 (3.7-4.5)
Glucose [mg/dl] (nmiss=4)	136 (113-173)	138 (116-238)	133 (111-168)
Lactate [mg/dl] (nmiss=4)	17 (13-29)	19 (12-34)	17 (14-29)

337

Table 1b	All patients*	SARS-CoV-2	SARS-CoV-2
	(n=160)	POC-PCR positive patients (n=16)	POC PCR negative patients (n=138)
Symptoms % (n)			
Fever	17.5 (28)	25.0 (4)	17.4 (24)
Cough	10.6 (17)	25.0 (4)	8.7 (12)
Haemoptysis	1.9 (3)	6.3 (1)	1.4 (2)
Sore throat	0 (0)	0 (0)	0 (0)
Rhinitis	0.6 (1)	0 (0)	0.7 (1)
Headache/muscle pain	8.8 (14)	12.5 (2)	8 (11)
Dyspnea	17.5 (28)	37.5 (6)	15.2 (21)
GI-Symptoms	5.6 (9)	6.3 (1)	5.8 (8)

Diarrhea	4.4 (7)	12.5 (2)	3.6 (5)
Nausea/emesis	13.1 (21)	12.5 (2)	13.8 (19)
Loss of smell	0 (0)	0 (0)	0 (0)
Abdominal pain	10 (16)	6.3 (1)	10.1 (14)
Chest pain	10.6 (17)	6.3 (1)	10.9 (15)
Severe COVID-19 risk factors % (n)			
Transplantation	3.8 (6)	0 (0)	4.3 (6)
Tumor	16.9 (27)	12.5 (2)	16.7 (23)
Cardiovascular disease	66.9 (107)	75.0 (12)	65.2 (90)
Respiratory disease	18.1 (29)	31.3 (5)	16.7 (23)
Renal disease	23.8 (38)	25.0 (4)	23.2 (32)
Hepatic disease	6.9 (11)	0 (0)	8.0 (11)
Pregnancy	1.3 (2)	6.3 (1)	0.7 (1)
Immunosuppression	10.6 (17)	0 (0)	12.3 (17)
Diabetes mellitus	23.1 (37)	31.3 (5)	21.0 (29)

338

339

Table 2	SARS-CoV-2 CL positive	Border-line	Weak	Inter-mediate	High	SARS-CoV-2 CL negative	No material	Total
SARS-CoV-2 POC positive	16					0		16
Borderline		2	1	0	0			
Weak		0	4	1	1			
Intermediate		0	0	0	2			
High		0	0	0	5			
SARS-CoV-2 POC negative	0					137	1	138
Error						6		6
Total	16					143	1	160

340

Table 3	All patients (n=160)	SARS-CoV-2 POC- PCR positive patients (n=16)	SARS-CoV-2 POC-PCR negative patients (n=138)
Inclusion criteria for inpatient treatment % (n)			
Acute severe trauma	5.6 (9)	6.3 (1)	5.8 (8)
Stroke	18.1 (29)	12.5 (2)	18.1 (25)
Myocardial Infarction	8.8 (14)	0 (0)	10.1 (14)
Urgent operation	22.5 (36)	0 (0)	25.4 (35)
Intervention needs within 6 hours after presentation	6.9 (11)	0 (0)	8.0 (11)
ICU admission needed within 6 hours after presentation	25.0 (40)	62.5 (10)	20.3 (28)
Other reasons	13.1 (21)	18.8 (3)	12.3 (17)
Clinical Course			
Intensive Care Unit % (n)	48.8 (78)	50.0 (8)	46.4 (64)
Intubation % (n)	15.6 (25)	18.8 (3)	13.8 (19)
Death % (n)*	10 (16)	25 (4)	7.2 (10)

341

Digitally integrated molecular testing of SARS-CoV-2 in the Emergency Department

*TT, testing time

342

343

344